Divalproex sodium (Depakote)
Small molecule
Evidence outlook
Approved: Migraine, Epilepsy, Absence Seizures, Bipolar Disorder, Focal Onset Seizures
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
Also approved (1)
- Mania Depakote (divalproex sodium) is a valproate and is indicated for the treatment of the manic episodes associated with bipolar disorder. A manic episode is a distinct period of abnormally and persistently elevated, expansive, or irritable mood. Typical symptoms of mania include pressure of speech, motor hyperactivity, reduced need for sleep, flight of ideas, grandiosity, poor judgment, aggressiveness, and possible hostility. The efficacy of Depakote was established in 3-week trials with patients meeting DSM-III-R criteria for bipolar disorder who were hospitalized for acute mania [see Clin
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT00221429 NCT00221429 · Bipolar Disorder Registry: NCT00221429 | 3 | Young Mania Rating Scale (YMRS) & Clinical Global Impressions I (CGI-I) (8 weeks) 2006-08 | YMRS fell by more than 50% in 56% on divalproex, 41% on lithium and 30% on placebo. | not yet graded | link ↗ |
View 1 more trial
NCT00194129 NCT00194129 · Bipolar Disorder This 6-month, randomized, double-blind trial enrolled patients with rapid-cycling bipolar disorder and substance abuse who had stabilized on lithium plus divalproex, and randomized 31 of them to continue both drugs or to switch divalproex to placebo. The primary outcome was time to a new mood episode. The median time was 17.8 weeks with the combination vs 15.9 weeks with lithium alone, a difference the paper reports as not significant, so the primary was missed. The sample was small. Source: the peer-reviewed paper (Kemp et al., J Clin Psychiatry 2009). Registry: NCT00194129 | 3 | Time to Treatment for Emerging Symptoms of a Mood Relapse (Up to 6 months) 2006-09 | Median time to a new mood episode over 6 months: 17.8 weeks with lithium plus divalproex vs 15.9 weeks with lithium plus placebo (not significant); relapse 53% vs 56% (Kemp et al., J Clin Psychiatry 2009). | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (22)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (1)
What this study did
Phase 2 (9)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (3)
What this study did
What this study did
What this study did
Phase 1 (13)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (28)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (7)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Used as active comparator (10)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 1 (9)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (1)
What this study did
Appears in other studies (3)
Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.
Phase 3 (2)
What this study did
What this study did
Phase 4 (1)
What this study did
Competitive landscape
Other GABAergic neurotransmission drugs
Divalproex sodium (Depakote ER), valproate. Compare all 3 GABAergic neurotransmission drugs
2 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Absence Seizures: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Divalproex Sodium (Depakote): this drug | Approved | Small molecule | GABAergic neurotransmission | not yet graded | No reviewed efficacy summary in this indication | |
| Divalproex Sodium (Depakote ER) | Approved | Small molecule | GABAergic neurotransmission | not yet graded | No reviewed efficacy summary in this indication | |
| Valproate | ApprovedUS marketing discontinued | Small molecule | GABAergic neurotransmission | not yet graded | No reviewed efficacy summary in this indication | |
| BMB-101 | Phase 2 | Small molecule | Serotonin 5-HT2C receptor (biased agonist) | not yet graded | No reviewed efficacy summary in this indication |
Compare side by side
Upcoming events
No upcoming readouts on record for this asset.